NDAORALTABLET
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
CENESTIN (estrogens, conjugated synthetic a) by Aspen Surgical is clinical pharmacology endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. First approved in 1999.
Drug data last refreshed 40m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CENESTIN is a synthetic conjugated estrogen tablet for oral administration approved in 1999. It replaces endogenous estrogen by binding to nuclear estrogen receptors and modulating gonadotropin secretion in postmenopausal women. The drug is indicated for management of vasomotor symptoms and other estrogen-deficiency conditions in postmenopausal women.
LOE Approaching
Product is approaching loss of exclusivity with low competitive pressure (30%), suggesting modest team size and focus on lifecycle extension or transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Endogenous estrogens are largely responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal…
Worked on CENESTIN at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.